ALGN vs ARQT
Align Technology vs Arcutis Biotherapeutics, Inc. — AI-powered side-by-side comparison
ALGN
Align Technology
73
Buy
VS
ARQT
Arcutis Biotherapeutics, Inc.
64
Buy
| Metric | ALGN | ARQT |
|---|
| AI Score |
73
|
64
|
| Price |
$172.86
|
$26.21
|
| P/E Ratio |
30.03×
|
118.80×
|
| ROE |
10.1%
|
-8.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
66.5%
|
91.1%
|
| Debt / Equity |
0.03×
|
0.52×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.1
|
44.7
|
| Beta |
1.653
|
1.526
|
| Expected Upside |
+7.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALGN versus ARQT.
ALGN leads by 9 points.
ALGN scores 73/100 (Buy) versus ARQT at 64/100 (Buy).
ALGN Committee View
100% agreement
5 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (sideways) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
ARQT Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 15.0% shows genuine earnings power backing the valuation — Value
- Revenue growing 76.1% YoY -- genuine top-line momentum — Growth
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- P/E of 114.1 is expensive by classic value standards — Value
- Price-to-book of 18.8x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical